CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study (Q39662185)

13 September 2017

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study (English)

1 reference

13 September 2017

0 references

1 reference

14

Roman A Blaheta

1 reference

13 September 2017

Ana Maria Waaga-Gasser

5

object named as

Ana Maria Waaga-Gasser

1 reference

13 September 2017

Igor Tsaur

1

1 reference

13 September 2017

Anika Noack

2

1 reference

13 September 2017

Jasmina Makarevic

3

1 reference

13 September 2017

Elsie Oppermann

4

1 reference

13 September 2017

Martin Gasser

6

1 reference

13 September 2017

Hendrik Borgmann

7

1 reference

13 September 2017

Tanja Huesch

8

1 reference

13 September 2017

Kilian M Gust

9

1 reference

13 September 2017

Michael Reiter

10

1 reference

13 September 2017

David Schilling

11

1 reference

13 September 2017

Georg Bartsch

12

1 reference

13 September 2017

Axel Haferkamp

13

1 reference

13 September 2017

13 October 2014

1 reference

Cancer Research and Treatment

13 September 2017

1 reference

13 September 2017

47

1 reference

13 September 2017

2

1 reference

13 September 2017

306-312

1 reference

CCL2 increases αvβ3 integrin expression and subsequently promotes prostate cancer migration

13 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Prioritizing genes associated with prostate cancer development

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Chemokines and chemokine receptors: an overview.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Multi-faceted roles for CXC-chemokines in prostate cancer progression

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

The chemokine network in cancer--much more than directing cell movement

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

CXC chemokines in angiogenesis of cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Chemokines in neoplastic progression

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Chemokines: agents for the immunotherapy of cancer?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Caveolin-1 as a potential high-risk prostate cancer biomarker.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398105

Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer

21 August 2018

1 reference

12 December 2020

CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer

1 reference

12 December 2020

Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA

1 reference

12 December 2020

Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner

1 reference

12 December 2020

Identifiers

DOI

10.4143/CRT.2014.015

1 reference

13 September 2017

1 reference

13 September 2017

PubMed publication ID

25483747

1 reference